AVDL Quote, Financials, Valuation and Earnings

Amarin Corp. Plc has a net margin of 0.03% compared to Avadel Pharmaceuticals Plc's net margin of -15.58%. Avadel Pharmaceuticals Plc's return on equity of -0.34% beat Amarin Corp. Plc's return on equity of -17.79%.

Avadel Pharmaceuticals Plc has a consensus price target of $20.94, signalling downside risk potential of -1.98%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -22.73%. Given that Amarin Corp. Plc has more downside risk than Avadel Pharmaceuticals Plc, analysts believe Avadel Pharmaceuticals Plc is more attractive than Amarin Corp. Plc.

Avadel Pharmaceuticals Plc has a beta of 1.262, which suggesting that the stock is 26.242% more volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.246%.

Avadel Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avadel Pharmaceuticals Plc pays -- of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend.

Avadel Pharmaceuticals Plc quarterly revenues are $77.5M, which are larger than Amarin Corp. Plc quarterly revenues of $49.4M. Avadel Pharmaceuticals Plc's net income of $20K is higher than Amarin Corp. Plc's net income of -$7.7M. Notably, Avadel Pharmaceuticals Plc's price-to-earnings ratio is 299.90x while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avadel Pharmaceuticals Plc is 8.45x versus 8.49x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.

Arcturus Therapeutics Holdings, Inc. has a net margin of 0.03% compared to Avadel Pharmaceuticals Plc's net margin of -95.02%. Avadel Pharmaceuticals Plc's return on equity of -0.34% beat Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98%.

Avadel Pharmaceuticals Plc has a consensus price target of $20.94, signalling downside risk potential of -1.98%. On the other hand Arcturus Therapeutics Holdings, Inc. has an analysts' consensus of $35.50 which suggests that it could grow by 438.7%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Avadel Pharmaceuticals Plc, analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Avadel Pharmaceuticals Plc.

Avadel Pharmaceuticals Plc has a beta of 1.262, which suggesting that the stock is 26.242% more volatile than S&P 500. In comparison Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, suggesting its more volatile than the S&P 500 by 110.246%.

Avadel Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avadel Pharmaceuticals Plc pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings, Inc. pays out -- of its earnings as a dividend.

Avadel Pharmaceuticals Plc quarterly revenues are $77.5M, which are larger than Arcturus Therapeutics Holdings, Inc. quarterly revenues of $14.2M. Avadel Pharmaceuticals Plc's net income of $20K is higher than Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M. Notably, Avadel Pharmaceuticals Plc's price-to-earnings ratio is 299.90x while Arcturus Therapeutics Holdings, Inc.'s PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avadel Pharmaceuticals Plc is 8.45x versus 2.10x for Arcturus Therapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of 0.03% compared to Avadel Pharmaceuticals Plc's net margin of 22.33%. Avadel Pharmaceuticals Plc's return on equity of -0.34% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

Avadel Pharmaceuticals Plc has a consensus price target of $20.94, signalling downside risk potential of -1.98%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $208.50 which suggests that it could grow by 24.78%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Avadel Pharmaceuticals Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Avadel Pharmaceuticals Plc.

Avadel Pharmaceuticals Plc has a beta of 1.262, which suggesting that the stock is 26.242% more volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.

Avadel Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avadel Pharmaceuticals Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Avadel Pharmaceuticals Plc quarterly revenues are $77.5M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Avadel Pharmaceuticals Plc's net income of $20K is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Avadel Pharmaceuticals Plc's price-to-earnings ratio is 299.90x while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avadel Pharmaceuticals Plc is 8.45x versus 2.45x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co. Plc has a net margin of 0.03% compared to Avadel Pharmaceuticals Plc's net margin of 1.22%. Avadel Pharmaceuticals Plc's return on equity of -0.34% beat Perrigo Co. Plc's return on equity of -0.66%.

Avadel Pharmaceuticals Plc has a consensus price target of $20.94, signalling downside risk potential of -1.98%. On the other hand Perrigo Co. Plc has an analysts' consensus of $24.50 which suggests that it could grow by 54.01%. Given that Perrigo Co. Plc has higher upside potential than Avadel Pharmaceuticals Plc, analysts believe Perrigo Co. Plc is more attractive than Avadel Pharmaceuticals Plc.

Avadel Pharmaceuticals Plc has a beta of 1.262, which suggesting that the stock is 26.242% more volatile than S&P 500. In comparison Perrigo Co. Plc has a beta of 0.386, suggesting its less volatile than the S&P 500 by 61.422%.

Avadel Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co. Plc offers a yield of 8.31% to investors and pays a quarterly dividend of $0.29 per share. Avadel Pharmaceuticals Plc pays -- of its earnings as a dividend. Perrigo Co. Plc pays out 94.9% of its earnings as a dividend. Perrigo Co. Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Avadel Pharmaceuticals Plc quarterly revenues are $77.5M, which are smaller than Perrigo Co. Plc quarterly revenues of $1B. Avadel Pharmaceuticals Plc's net income of $20K is lower than Perrigo Co. Plc's net income of $12.7M. Notably, Avadel Pharmaceuticals Plc's price-to-earnings ratio is 299.90x while Perrigo Co. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avadel Pharmaceuticals Plc is 8.45x versus 0.45x for Perrigo Co. Plc. Usually stocks with elevated PS ratios are considered overvalued.